By: Benzinga
March 07, 2013 at 10:50 AM EST
UPDATE: Wedbush Raises PT to $13 on Sangamo BioSciences on HIV Progress, Time Value
Wedbush maintained Sangamo BioSciences (NASDAQ: SGMO ) with an Outperform rating and raised the price target from $10.00 to $13.00. Wedbush said, "Sangamo presented immunologic results supporting previous observations about the functionality and durability of SB-728-T modified T-cells at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). … We
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here